Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
Mar 18, 10:21 AM
W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.
Key Timestamps
01:04 - Guest Introduction
03:45 - FDA Indication for Obesity
08:45 - SURMOUNT-2
17:40 - SURMOUNT-3 and -4
22:00 - Future of Incretin Therapies
Key Timestamps
01:04 - Guest Introduction
03:45 - FDA Indication for Obesity
08:45 - SURMOUNT-2
17:40 - SURMOUNT-3 and -4
22:00 - Future of Incretin Therapies